Floatz logo

Incb099280

Esophageal Squamous Cell Carcinoma

Incyte CorporationPhase 1Dormant
C
32/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
19/ 100
Competitive Position
73/ 100

Competitive context

65 Active assets in the Esophageal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
AstraZeneca
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Levoleucovorin
Taiho Oncology, Inc.
Phase 3BB
Cetuximab
Hummingbird Bioscience
Phase 2B

View all 50 →

Same molecule, other indications

Incb099280 is also rated in:

cancerDormant
CC
Indicative ·
42 / 100
View asset →
cutaneous neuroendocrine carcinomaDormant
C
Indicative ·
34 / 100
View asset →
MSI-H/dMMR TumorsDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →